Ceftaroline

Restricted
Restricted

C. diff Risk

Medium

Oral Bioavailability

NA

Approximate Cost

Dosing

Requires Infectious Disease consultation for use OR completion of the Restricted Antimicrobial order form for approved indications 600 mg IV every 12 hr

General Information

Acceptable Uses

Allegry to beta-lactams/vancomycin and/or resistant to other antimicrobials and one of the following criteria met:

  • Treatment of skin or soft tissue infection

  • Failed treatment with ceftriaxone for community aquired pneumonia

Unacceptable Uses

  • Selected over vancomycin in patients with renal failure

Common Usage

Ceftaroline is approved for treatment of skin and skin structure infections (including those caused by MSRA) and community aquired pneumonia.

Drug Monitoring

Lab

  • SCr

Clinical

  • Hypersensitivity

  • Diarrhea

  • GI effects

Adverse Effects

  • Hypersenistivty reactions

  • GI effects including diarrhea

Pharmacology

Pregnancy category: Adverse events have been observed in some animal reproduction studies

Average serum half life: 1.6 hr (single dose), 2.66 hr (multiple doses)

Urine penetration: Excellent

Route of Elimination: Urine